http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
고윤화,손용훈,윤정흠,오상우,이귀행,박민철 圓光大學校 醫科學硏究所 2008 圓光醫科學 Vol.23 No.2
Background: Minnesota multiphasic personality inventory-2(MMPI-2) is superior to its predecessor in differential diagnosis. this study was to investigate MMPI-2 profiles of the patients with schizophrenia and depression and to discriminate among two groups. Methods: The sample consisted of 35 patients with schizophrenia(male 24, female 11), 35 patients with depression(male 18, female 17) diagnosed by the diagnostic and statistical manual of mental disorders(DSM-IV) for schizophrenia & depression at department of neuropsychiatry in WonKwang University from January 2005 to December 2007. The data from the results were analyzed statistically by t-test and discriminant analysis. Results: The results were as follows. First, according to t-test results the comparison of schizophrenia patients and depression patients in MMPI-2 among two groups showed significant differences; the validity scales: F, F(P); The clinical scales: D, Pa; The restructured clinical scales: Rcd(dem), RC4, RC6, RC8; The content scales: ANX, DEP, BIZ; The supplementary scales: AGGR, PSYC, Mt, GF, O-H. Second, as a results discriminant analysis, BIZ, D were significant predictors in distinguishing patients with schizophrenia from patients with depression. Third, probability to be discriminated schizophrenia in schizophrenia was 91.4%, probability to be discriminated depression in depression was 85.7%. Conclusion: Finally, we remind readers that although the MMPI-2 may prove to be useful in the task of differential diagnosis, it should be used only in combination with other patient information. 배경: MMPI-2는 감별진단에서 기존의 MMPI 보다 더 우수하다. 본 연구는 정신분열증 환자와 우울증 환자의 MMPI-2 프로파일과 두 집단을 판별하는 연구를 하였다. 방법: 2005년 1월부터 2007년 12월까지 원광대학교 병원 신경정신과에서 정신분열증과 우울증으로 진단된 정신분열증 환자 35명(남성 24명, 여성 11명), 우울증 환자 35명(남성 18명, 여성 17명)이 본 연구에 참여하였다. 자료는 t-검증과 판별분석으로 분석하였다. 결과: 결과는 다음과 같다. 1. t-검증 결과, 두 집단간 유의미한 차이를 보인 척도들로는 타당도 척도에서 F, F(P) 척도, 임상척도에서 D, Pa, 척도, 재구성 임상척도에서 Rcd(dem), RC4, RC6, RC8척도 였다. 내용척도에서는 ANX, DEP, BIZ척도 였으며 보충척도에서는 AGGR, PSYC, MT, GF O-H척도 였다. 2. 판별 분석 결과로서, 정신분열증과 우울증을 구별하는데 가장 유의한 예언요소는 BIZ, D척도로 나타났다. 3. 판별함수를 통한 진단율은 정신분열증을 정신분열증으로 판별해주는 정확도는 91.4%였고, 우울증을 우울증으로 판별해주는 정확도는 85.7%였다. 결론: 본 연구 결과를 통해서 MMPI-2가 두 집단을 감별하는데 유용하다고 증명되었을지 모르지만 더욱 정확하게 감별하기 위해서 환자의 기타 정보를 사용해야 할 것이다.
( Hyeon Jeong Goong ),( Jong Ho Moon ),( Yun Nah Lee ),( Hyun Jong Choi ),( Seo-youn Choi ),( Moon Han Choi ),( Min Jin Kim ),( Tae Hoon Lee ),( Sang-heum Park ),( Hae Kyung Lee ) 대한간학회 2017 Gut and Liver Vol.11 No.3
Background/Aims: Treatment for cholangitis without common bile duct (CBD) stones has not been established in patients with gallstones. We investigated the usefulness of endoscopic biliary drainage (EBD) without endoscopic sphincterotomy (EST) in patients diagnosed with gallstones and cholangitis without CBD stones by endoscopic retrograde cholangiopancreatography (ERCP) and intraductal ultrasonography (IDUS). Methods: EBD using 5F plastic stents without EST was performed prospectively in patients with gallstones and cholangitis if CBD stones were not diagnosed by ERCP and IDUS. After ERCP, all patients underwent laparoscopic cholecystectomy. The primary outcomes were clinical and technical success. The secondary outcomes were recurrence rate of biliary events and procedure-related adverse events. Results: Among 187 patients with gallstones and cholangitis, 27 patients without CBD stones according to ERCP and IDUS received EBD using 5F plastic stents without EST. The stents were maintained in all patients until laparoscopic cholecystectomy, and recurrence of cholangitis was not observed. After cholecystectomy, the stents were removed spontaneously in 12 patients and endoscopically in 15 patients. Recurrence of CBD stones was not detected during the follow-up period (median, 421 days). Conclusions: EBD using 5F plastic stents without EST may be safe and effective for the management of cholangitis accompanied by gallstones in patients without CBD stones according to ERCP and IDUS. (Gut Liver 2017;11:434-439)